Table 2. Correlation of HELLS, ZIC2 and ZIC5 with clinicopathologic parameters.

HELLS
	Negative	Positive	Total	p-value
PSA at diagnosis				0.71
≤ 10 ng/ml	312 (74.3%)	55 (13.1%)	367 (87.4%)
> 10 ng/ml	44 (10.5%)	9 (2.1%)	53 (12.6%)
Total	356 (84.8%)	64 (15.2%)	420
Gleason score				< 0.001
< 7	198 (47.0%)	23 (5.5%)	221 (52.5%)
7	143 (34.0%)	29 (6.8%)	172 (40.8%)
> 7	16 (3.8%)	12 (2.9%)	28 (6.7%)
Total	357 (84.8%)	64 (15.2%)	421
pT-stage				0.07
pT2	257 (61.1%)	37 (8.8%)	294 (69.9%)
pT3a/b	81 (19.2%)	21 (5.0%)	102 (24.2%)
pT4	19 (4.5%)	6 (1.4%)	25 (5.9%)
Total	357 (84.8%)	64 (15.2%)	421

ZIC2
	Negative	Positive	Total	p-value
PSA at diagnosis				0.66
≤ 10 ng/ml	176 (52.9%)	108 (32.4%)	284 (85.3%)
> 10 ng/ml	32 (9.6%)	17 (5.1%)	49 (14.7%)
Total	208 (62.5%)	125 (37.5%)	333
Gleason score				0.18
< 7	98 (29.5%)	61 (18.3%)	159 (47.8%)
7	88 (26.4%)	58 (17.4%)	146 (43.8%)
> 7	22 (6.6%)	6 (1.8%)	28 (8.4%)
Total	208 (62.5%)	125 (37.5%)	333
pT-stage				0.77
pT2	136 (40.9%)	83 (24.9%)	219 (65.8%)
pT3a/b	58 (17.4%)	36 (10.8%)	94 (28.2%)
pT4	14 (4.2%)	6 (1.8%)	20 (6.0%)
Total	208 (62.5%)	125 (37.5%)	333

ZIC5
	Negative	Positive	Total	p-value
PSA at diagnosis				0.13
≤ 10 ng/ml	237 (57.4%)	122 (29.5%)	359 (86.9%)
> 10 ng/ml	30 (7.3%)	24 (5.8%)	54 (13.1%)
Total	267 (64.7%)	146 (35.3%)	413
Gleason score				< 0.001
< 7	161 (38.9%)	61 (14.7%)	222 (53.6%)
7	94 (22.7%)	70 (16.9%)	164 (39.6%)
> 7	12 (2.9%)	16 (3.9%)	28 (6.8%)
Total	267 (64.5%)	147 (35.5%)	414
pT-stage				0.25
pT2	193 (46.6%)	95 (23.0%)	288 (69.6%)
pT3a/b	58 (14.0%)	42 (10.1%)	100 (24.1%)
pT4	16 (3.9%)	10 (2.4%)	26 (6.3%)
Total	267 (64.5%)	147 (35.5)	414

For HELLS and ZIC5 a cut-off of 1% was applied, for ZIC2 a cut-off of 50%.